| Understanding inter-individual variability in monoclonal antibody disposition VA Thomas, JP Balthasar Antibodies 8 (4), 56, 2019 | 66 | 2019 |
| GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys SC Lu, M Chen, L Atangan, EA Killion, R Komorowski, Y Cheng, ... Cell Reports Medicine 2 (5), 2021 | 55 | 2021 |
| A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings MM Véniant, SC Lu, L Atangan, R Komorowski, S Stanislaus, Y Cheng, ... Nature Metabolism 6 (2), 290-303, 2024 | 46 | 2024 |
| Measurement and Quantitative Characterization of Whole-Body Pharmacokinetics of Exogenously Administered T Cells in Mice RCKDKS Antari Khot, Matsueda Satoko, Veena A Thomas Journal of Pharmacology and Experimental Therapeutics, 2019 | 45 | 2019 |
| Hallmarks of neurodegenerative disease: A systems pharmacology perspective P Bloomingdale, T Karelina, V Ramakrishnan, S Bakshi, ... CPT: Pharmacometrics & Systems Pharmacology 11 (11), 1399-1429, 2022 | 33 | 2022 |
| The biodistribution of therapeutic proteins: Mechanism, implications for pharmacokinetics, and methods of evaluation KP Conner, SC Devanaboyina, VA Thomas, DA Rock Pharmacology & therapeutics 212, 107574, 2020 | 28 | 2020 |
| Sorafenib decreases tumor exposure to an anti-carcinoembryonic antigen monoclonal antibody in a mouse model of colorectal cancer VA Thomas, JP Balthasar The AAPS journal 18, 923-932, 2016 | 12 | 2016 |
| Development of in silico models to predict viscosity and mouse clearance using a comprehensive analytical data set collected on 83 scaffold-consistent monoclonal antibodies M Mock, AW Jacobitz, CJ Langmead, A Sudom, D Yoo, SC Humphreys, ... MAbs 15 (1), 2256745, 2023 | 9 | 2023 |
| Preclinical characterization of the ADME properties of a surrogate anti-IL-36R monoclonal antibody antagonist in mouse serum and tissues MWDAR Kip P. Conner,Cinthia V. Pastuskovas,Marcus Soto,Veena A. Thomas mAbs 12 (1), 2020 | 5 | 2020 |
| Utility of physiologically based pharmacokinetic modeling to predict inter-antibody variability in monoclonal antibody pharmacokinetics in mice S Liu, SC Humphreys, KD Cook, KP Conner, AR Correia, AW Jacobitz, ... Mabs 15 (1), 2263926, 2023 | 1 | 2023 |
| Rapid depletion of “catch-and-release” anti-ASGR1 antibody in vivo SC Devanaboyina, P Li, EL LaGory, C Poon-Andersen, KD Cook, M Soto, ... Mabs 16 (1), 2383013, 2024 | | 2024 |
| Correlation of In Vitro Kinetic Stability to Preclinical In Vivo Pharmacokinetics for a Panel of Anti-PD-1 Monoclonal Antibody Interleukin 21 Mutein Immunocytokines KD Cook, T Tran, VA Thomas, SC Devanaboyina, DA Rock, JT Pearson Drug Metabolism and Disposition 52 (3), 228-235, 2024 | | 2024 |
| Investigation of Inter-individual Variability in Monoclonal Antibody Disposition VA Thomas State University of New York at Buffalo, 2018 | | 2018 |
| Development of a PBPK model for anti-transferrin (TfR) antibodies to predict brain and systemic pharmacokinetics V Thomas, P Glassman, J Balthasar JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 44, S29-S29, 2017 | | 2017 |
Antari KhotTakeda clinical pharmacology在 buffalo.edu 的电子邮件经过验证
